ICON1: Treatment Decisions and Outcomes in Pediatric Refractory ITP

Not Recruiting

Trial ID: NCT01971684


The purpose of this study is to understand physician treatment decisions in selecting specific second line treatments in pediatric ITP and to determine the effectiveness of different second line ITP treatments. Eligible patients are those ages 1-18 years who are starting on a new second line treatment for ITP, defined as any treatment other than IVIG, steroids, anti-D globulin, or aminocaproic acid. Enrolled patients remain on the study for approximately one year.

Official Title

ICON1: Physician Treatment Decisions and Patient-Reported Outcomes in Pediatric Refractory Immune Thrombocytopenia

Stanford Investigator(s)


Inclusion Criteria:

   - Immune Thrombocytopenia or Evans Syndrome

   - Ages > 12 months to <18 years

   - Starting a new second line therapy as defined as any therapy except IVIG, steroids,
   anti-D globulin, or aminocaproic acid

   - Starting a single agent/monotherapy

Exclusion Criteria:

   - Evans Syndrome with a history of or current evidence of autoimmune hemolytic anemia

   - Unwillingness to be followed for 1 year

   - Physician providing care is unwilling to participate

   - Patient is starting multiple second line agents simultaneously


drug: Second Line ITP agents

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Michael Jeng